Finvest
MIRM Biotechnology · Rare disease · Liver disease · Commercial biotech · Thesis updated July 19, 2026

Rare liver growth, rich expectations

01 Running thesis

Growth is real, patience is required

Mirum has moved from a single rare liver story into a broader rare disease company. Its core drug, LIVMARLI, treats severe itching tied to rare liver diseases. The bull case is simple: keep finding more eligible patients, keep payers covering the drug, and use the same liver doctor network to launch more products.

The latest setup is stronger than it was a year ago. Management raised full year 2026 revenue guidance to $660 million to $680 million, helped by PFIC demand and adult patient uptake. The company is also expanding its U.S. field commercial team to about 60 people so it can reach more than 4,000 liver health care professionals.

The pipeline gives Mirum several ways to grow beyond today’s sales. Volixibat could add PSC and PBC opportunities. Brelovitug adds chronic HDV, a serious viral hepatitis market. Zilurgisertib, if approved for FOP, could become a new rare genetic disease business, with management pointing to more than $200 million in global peak sales potential.

The bear case is not about whether Mirum has products. It does. The worry is price, execution, and time. Rare disease markets are small, launches can stall if adult doctors do not adopt quickly, and recent deals add cost before they add revenue. Management still expects operating cash flow to turn positive in 2027, but GAAP profitability is pushed to 2028 because R&D spending stays heavy.

May 2026Mirum raised full year 2026 revenue guidance to $660 million to $680 million after strong demand across brands, led by LIVMARLI PFIC uptake. Management also said it expects operating cash flow to turn positive in 2027, while GAAP profitability is pushed to 2028.
May 2026Volixibat produced positive VISTAS Phase 2b topline results in PSC, and Mirum now expects an NDA submission in the second half of 2026. The company also added zilurgisertib commercial rights, with an FDA action date of September 26, 2026.
Feb 2026The Bluejay acquisition added brelovitug for chronic HDV infection. This moved Mirum further into viral hepatitis and added AZURE-1 and AZURE-4 Phase 3 readouts expected in the second half of 2026.
Nov 2025Mirum posted a brief net income milestone in Q3 2025, but warned losses would likely continue as it funds trials and commercial work. Volixibat timelines also became clearer, with PSC data expected in Q2 2026 and PBC data expected in the first half of 2027.
Aug 2025The thesis stayed mostly intact. Mirum planned to start a Phase 2 trial of MRM-3379 in Fragile X syndrome in Q4 2025, while Q2 2025 revenue included an $11 million estimate change tied to partner inventory pricing approvals.
May 2025Takeda received Japanese approval for LIVMARLI in ALGS and PFIC, adding to the international footprint. Management also gave firmer volixibat timelines for PSC and PBC.
Feb 2025Ctexli received FDA approval for adults with CTX, resolving a key regulatory catalyst. Mirum also added MRM-3379 for Fragile X syndrome, broadening the pipeline beyond liver and bile acid disease.
Nov 2024Mirum submitted the chenodiol NDA for CTX and received FDA Breakthrough Therapy Designation for volixibat in PBC. These updates added near-term regulatory and clinical catalysts to the story.
02 Business model

Selling scarce medicines to small markets

Mirum makes money by selling approved medicines for rare diseases. These are not mass market drugs. They are aimed at small patient groups where treatment options are limited and pricing can be high if insurers agree the drug matters.

The company sells directly in the United States and some European countries. In other places, it uses partners and distributors. Takeda, for example, handles LIVMARLI in Japan under a licensing and supply deal.

This model can be powerful once a medicine is approved. Sales teams can target a clear group of specialists, and a small number of diagnosed patients can still support large revenue. The weak point is that every patient matters. If diagnosis, reimbursement, safety, or doctor education slips, growth can slow fast.

Mirum also buys or licenses assets to widen its base. That can speed growth, but it raises the bill for research, milestones, royalties, and commercial buildout. The Bluejay deal brought brelovitug, while the Incyte deal brought rights to commercialize zilurgisertib if approved.

03 Product portfolio

Approved drugs and bought options

Growth engine

LIVMARLI

LIVMARLI is approved for cholestatic pruritus in Alagille syndrome and PFIC. It is Mirum’s largest product by Q1 2026 sales and the main reason management raised 2026 guidance.

Steady

Cholbam and Ctexli

Cholbam treats bile acid synthesis disorders, and Ctexli treats adults with CTX. Mirum groups these as bile acid medicines in its revenue table.

Option

Volixibat

Volixibat is being advanced for PSC and PBC, two liver diseases where itching can be severe. Mirum expects to submit an NDA for PSC in the second half of 2026 based on VISTAS Phase 2b topline results.

Option

Brelovitug

Brelovitug came from the January 2026 Bluejay acquisition. It targets chronic hepatitis D virus, and AZURE-1 and AZURE-4 topline results are expected in the second half of 2026.

Option

Zilurgisertib

Mirum acquired rights from Incyte to commercialize zilurgisertib if approved for fibrodysplasia ossificans progressiva. The FDA action date is September 26, 2026, and management sees more than $200 million in global peak sales potential.

Option

MRM-3379

MRM-3379 is an oral CNS-penetrant PDE4D inhibitor for Fragile X syndrome. It expands Mirum beyond liver and bile acid disease into neurocognitive disorders.

04 Business segments

One segment, two sales buckets

LIVMARLI product sales71%growing fast
Bile acid medicines product sales29%modest

Mirum says it manages the company as one operating segment. For Q1 2026 product sales, LIVMARLI produced $113.804 million and bile acid medicines produced $46.078 million, out of $159.882 million total product sales.

05 Risk factors

What could break the story

Adult PFIC launch slows

High impact · Medium odds

The 2026 guidance raise depends on strong LIVMARLI demand, including adult PFIC uptake. Mirum is expanding its field team to reach adult liver care settings, but hiring reps does not guarantee prescriptions. If adult hepatologists do not adopt LIVMARLI quickly, the growth story weakens.

We watchQuarterly LIVMARLI sales, guidance changes, and comments on adult PFIC prescriber growth.

Reimbursement or pricing pressure

High impact · Medium odds

Rare disease drugs often depend on high prices and broad insurance coverage. Mirum must keep payers convinced that its approved medicines are worth covering. More denials, bigger rebates, or tougher government pricing could reduce net sales.

We watchNet product sales versus prescription demand, gross-to-net commentary, and payer access updates.

Pipeline catalysts disappoint

High impact · Medium odds

A lot of the upside now sits in volixibat, brelovitug, zilurgisertib, and MRM-3379. These assets target serious diseases, but trial results and FDA reviews can still fail. A negative volixibat NDA path, weak AZURE data, or a zilurgisertib rejection would cut future growth hopes.

We watchVolixibat NDA timing, AZURE-1 and AZURE-4 readouts, and the September 26, 2026 zilurgisertib PDUFA decision.

Deal integration and spending run hot

Medium impact · Medium odds

Mirum has added assets through deals, including Bluejay and the Incyte commercial rights. These moves bring new science, new teams, new obligations, and new launch work. The company already pushed GAAP profitability to 2028 because R&D spending remains heavy.

We watchOperating cash flow progress toward 2027, R&D expense, SG&A expense, and acquisition-related milestone obligations.

Supply and channel concentration

Medium impact · Low odds

Mirum relies on a single third-party logistics provider and a single specialty pharmacy for all sales of approved medicines in the United States and Canada. That makes distribution simpler, but it creates a bottleneck. A service failure could disrupt patient access and reported sales.

We watchAny filing disclosure about specialty pharmacy, distributor, or third-party logistics disruption.
06 Quick answers

In one breath

What does Mirum Pharmaceuticals do?

Mirum sells medicines for rare diseases, mainly rare liver and bile acid disorders. Its biggest product is LIVMARLI, which treats severe itching linked to Alagille syndrome and PFIC.

Why is LIVMARLI so important to MIRM stock?

LIVMARLI is the main growth driver today. In Q1 2026, it made up the larger part of product sales, and strong PFIC demand helped management raise full year 2026 revenue guidance.

When could Mirum become profitable?

Management expects operating cash flow to turn positive in 2027. GAAP profitability, which includes more accounting costs and heavy R&D spending, is now expected in 2028.

What are the next big Mirum catalysts?

Key events include a possible volixibat NDA submission for PSC in the second half of 2026, AZURE trial results for brelovitug in the second half of 2026, and the September 26, 2026 FDA action date for zilurgisertib.